Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free
Close

OUTLOOK THERAPEUTICS INC (OTLK)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow OUTLOOK THERAPEUTICS's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.250 -0.020    -1.57%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
1.340
+0.090
+7.200%
18:47:20 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 581,936
  • Bid/Ask: 1.270 / 1.340
  • Day's Range: 1.210 - 1.290
OUTLOOK THERAPEUTICS 1.250 -0.020 -1.57%

OTLK Earnings

 
The latest earnings per stock, revenues and financial reports for OUTLOOK THERAPEUTICS INC (OTLK).
InvestingPro Earnings Insights
Latest Release

Aug 10, 2022

EPS / Forecast

-0.08 / -0.0733

Revenue / Forecast

0.00 / 0.00

Revenue
EPS
 Forecast
 
Release Date Period End EPS /  Forecast Revenue /  Forecast
Dec 21, 2022 09/2022 -- /  -0.07 -- /  0.00
Aug 10, 2022 06/2022 -0.08 /  -0.0733 0.00 /  0.00
May 13, 2022 03/2022 -0.09 /  -0.06 0.00 /  0.00
Feb 14, 2022 12/2021 -0.08 /  -0.06 0.00 /  0.00
Dec 22, 2021 09/2021 -0.08 /  -0.0633 0.00 /  300K
Aug 13, 2021 06/2021 -0.07 /  -0.07 0.00 /  0.00
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View upcoming earnings forecasts and in-depth analysis of company forecasts.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

OTLK Comments

Write your thoughts about OUTLOOK THERAPEUTICS INC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Pedro Felgueiras
Pedro Felgueiras Feb 13, 2022 8:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial OperationsJoel Prieve brings nearly 20 years of commercial operations expertise and proven track record in sales and account managementISELIN, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.“Outlook Therapeutics is thrilled to welcome Joel to our executive leadership team. We believe his background and expertise in commercialization and specialty biopharmaceutical distribution will be invaluable as we continue advancing our pre-launch commercial planning in anticipation of potential approval for ONS-5010 ophthalmic bevacizumab,” stated Jeff Evanson, Chief Commercial Officer of Outlook Therapeutics.Mr. Prieve has nearly twenty years of experience in commercial operations, most recently in the Xcenda division of AmerisourceBergen as Vice President of Business Development and previously in the IPN Solutions division. Over the course of his career, he has amassed valuable leadership experience in sales management and national account management across oncology and specialty biopharmaceutical markets. His expertise in Group Purchasing Organization (GPO) contracting for retina/ophthalmology markets and his proven track record of successful partnerships for new product launches will be key for Outlook Therapeutics’ advancement of ONS-5010 / LYTENAVA ™ (bevacizumab-vikg) towards potential commercialization.In his new role as SVP of Commercial Operations, Mr. Prieve will report to Jeff Evanson, Chief Commercial Officer of Outlook Therapeutics, and oversee all aspects of distribution, third-party logistics, HUB services and field resources to deliver an industry-leading customer experience.Mr. Prieve added, “I am delighted to join Outlook Therapeutics at such an important stage of its development. I look forward to working with Jeff and the rest of the team on the potential commercial launch of ONS-5010.” Outlook Therapeutics expects to submit a Biologics License Application (BLA) for ONS-5010 ophthalmic bevacizumab with the U.S. Food and Drug Administration (FDA) during the first quarter of 2022. In anticipation of potential FDA marketing approval in late 2022 or early 2023, Outlook Therapeutics’ commercial launch planning includes manufacturing with drug substance manufacturer FUJIFILM Diosynth Biotechnologies and best-in-class drug product manufacturer Aji Biopharma Services, distribution, sales force planning, physician and payor advisory board outreach, key opinion leader support and payor community engagement.To bring ONS-5010 to market in a way that benefits all stakeholders – patients, clinicians and payors – Outlook Therapeutics is in collaborative discussions with payors and the retina community. Outlook Therapeutics is also developing registration documents on a parallel path for approvals in Europe and expects to submit them in the fourth quarter of 2022. Outlook Therapeutics continues to explore potential strategic commercialization partners, such as Syntone Biopharma JV in China. Outlook Therapeutics expects ONS-5010, if approved, to be a safe and cost-effective choice for patients, clinicians and payors worldwide for retinal indications.
Lena Yturria
Lena Yturria Dec 02, 2021 10:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ONS-5010. Hay incongruencias en fechas de aprobacion en las diferentes plataformas de consulta. Alguien puede aclarar (2021 o 2022?)
Pedro Felgueiras
Pedro Felgueiras Aug 27, 2021 8:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Outlook Therapeutics (NASDAQ:OTLK) shareholder returns have been splendid, earning 198% in 1 year
Pedro Felgueiras
Pedro Felgueiras Aug 27, 2021 7:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
OTLK Price Targets:8,00 : Brookline Capital Markets, Following Clinical Business Update8,00/7,00/6,00 : BARCHART8,00/6,67/6,00 : YAHOO FINANCE (BUY) ; BARRONS (BUY) ; WEBULL (BUY) ; WSJ (BUY) ; STOCK NEWS (BUY) ; MARKET SCREENER (BUY) ; NASDAQ [STRONG BUY]8,00/6,00/6,00 : CNN BUSINESS (BUY) ; MARKET WATCH (BUY)7,00 ; ZACKS6,00 ; TIPRANKS (Moderate Buy) ; H C WAINWRIGHT ; MARKETBEAT [BUY]
Pedro Felgueiras
Pedro Felgueiras Aug 27, 2021 7:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
As expected..... buying pressure began last friday and continues .... Institutions have taken positions and built a base. We are in a Uptrend, Last "6 days" of OTLK continuous in a Uptrend.
Luca Lanzoni
Luca Lanzoni Aug 04, 2021 10:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I closed yestrday my position on OTLK but very interested to join again, what are you targets?
Deepak Kalwani
Deepak Kalwani Feb 16, 2021 12:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is going to 8 soon
ramakrishna kadukuntla
ramakrishna kadukuntla Feb 16, 2021 12:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Can you explain Why ? please
Deepak Kalwani
Deepak Kalwani Feb 16, 2021 12:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
U need to do your research
ramakrishna kadukuntla
ramakrishna kadukuntla Feb 16, 2021 12:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Deepak Kalwani  i did mine and want to know if my research is on right track.
Mike Darby
Mike Darby Feb 11, 2021 7:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Told you this was a garbage pump and dump stock
Aaron Agresta
Aaron Agresta Feb 10, 2021 8:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dump or HOLD ??
Feb 10, 2021 8:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hold
Aaron Agresta
Aaron Agresta Feb 09, 2021 1:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
flatline
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email